Montelukast in hospitalized patients diagnosed with COVID-19.

ABSTRACT:

Objective

Several therapeutic agents have been assessed for the treatment of COVID-19, but few approaches have been proven efficacious. Because leukotriene receptor antagonists, such as montelukast have been shown to reduce both cytokine release and lung inflammation in preclinical models of viral influenza and acute respiratory distress syndrome, we hypothesized that therapy with montelukast could be used to treat COVID-19. The objective of this study was to determine if montelukast treatment would reduce the rate of clinical deterioration as measured by the COVID-19 Ordinal Scale.

Methods

We performed a retrospective analysis of COVID-19 confirmed hospitalized patients treated with or without montelukast. We used "clinical deterioration" as the primary endpoint, a binary o

SUBMITTER: Khan AR 

PROVIDER: S-EPMC7938648 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature